Victory Capital Management
IMDX

Victory Capital Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Victory Capital Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-821
Closed -$3.78K – 2542
2023
Q2 		$3.78K Buy
821
+229
+39% +$1.15K ﹤0.01% 2507
2023
Q1 		$4.19K Sell
592
-34
-5% -$252 ﹤0.01% 2577
2022
Q4 		$4.02K Hold
626
– – ﹤0.01% 2571
2022
Q3 		$9K Sell
626
-132
-17% -$2.29K ﹤0.01% 2665
2022
Q2 		$14K Sell
758
-12
-2% -$273 ﹤0.01% 2636
2022
Q1 		$18K Buy
770
+139
+22% +$4.44K ﹤0.01% 2646
2021
Q4 		$27K Sell
631
-15
-2% -$863 ﹤0.01% 2677
2021
Q3 		$46K Buy
646
+16
+3% +$1.47K ﹤0.01% 2691
2021
Q2 		$72K Sell
630
-37
-6% -$3.61K ﹤0.01% 2638
2021
Q1 		$69K Buy
+667
New +$63.3K ﹤0.01% 2639
2020
Q2 		– Sell
-862
Closed -$42K – 3019
2020
Q1 		$42K Buy
+862
New +$42.3K ﹤0.01% 2841
2019
Q4 		– Sell
-290
Closed -$12K – 3054
2019
Q3 		$12K Buy
+290
New +$11.4K ﹤0.01% 3195

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Victory Capital Management's IMDX Position: Q3 2023 in Review

Victory Capital Management sold out of Insight Molecular Diagnostics (IMDX) in Q3 2023, closing a stake of 821 shares — an estimated $3.78K sold.

Victory Capital Management first reported a position in IMDX in Q3 2019 and held it in 12 quarters. The position peaked at $72K in Q2 2021. 30 funds tracked by Wall St. Rank hold IMDX as of Q3 2023.

  • Victory Capital Management reported no remaining Insight Molecular Diagnostics position as of Q3 2023 after selling out during the quarter.
  • Victory Capital Management sold 821 Insight Molecular Diagnostics shares in Q3 2023, an estimated $3.78K.
  • Victory Capital Management first reported a position in Insight Molecular Diagnostics in Q3 2019 and held it in 12 quarters.
  • Victory Capital Management's Insight Molecular Diagnostics position peaked at $72K in Q2 2021.
  • 30 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2023.

Based on Victory Capital Management's 13F filing for Q3 2023, filed 6 Nov 2023.